How do you know?? FDA doesn't do holds without significant serious safety issues, like deaths. NWBO has refused to report to investors the cause of the hold -- it is material and should be reported. It did cause NWBO to cancel the trial prematurely.
Sorry, only a handful of clinicians including Dr. Bosch and his statistical consultants prepared the manuscript. Vast majority of "authors" were clinical trial site clinicians. It's how the publication game works. They get author credit without having to write the article.
The compassionate care has not been updated since 2016 -- is it even operating?? The other trial is an NIH sponsored trial so FDA will give them leeway. If it was an NWBO sponsored trial (it is not), they would have been under the trial hold. Bad examples.
Market Data 
Markets 
AI
